Basic Xatral Information

• INN (International Nonproprietary Name): Alfuzosin.
• Brand Names Available In United Kingdom: Xatral; alfuzosin generics marketed as Alfuzosin Teva, Alfuzosin Mylan, Alfuzosin Sandoz and other local generics.
• ATC Code: G04CA01.
• Forms & Dosages: Extended/prolonged‑release tablets, commonly 10 mg once daily; some generics available as 5 mg and rarely 2.5 mg formulations; packaging typically blister packs of 30 or 60 tablets.
• Manufacturers In United Kingdom: Originator/major supplier listed as Sanofi; common generic suppliers in UK/EU markets include Teva, Sandoz, Mylan, Krka, Actavis and Torrent.
• Registration Status In United Kingdom: MHRA‑authorised for use in adult men with benign prostatic hyperplasia.
• OTC / Rx Classification: Prescription‑only (Rx).

Key Findings From Recent Trials

Major 2022–2025 Studies

What did recent trials actually show about alfuzosin for men with LUTS/BPH?

High‑quality randomised trials and pooled analyses between 2022 and 2025 compared alfuzosin 10 mg extended‑release with placebo and with other alpha‑blockers in men with lower urinary tract symptoms attributed to benign prostatic hyperplasia.

The principal end points used across these trials were IPSS (International Prostate Symptom Score), Qmax (peak urinary flow) and patient‑reported quality of life measures.

Main Outcomes

Can men expect to feel better — and how quickly?

Across studies, alfuzosin 10 mg ER produced clinically meaningful reductions in IPSS often apparent within days to a few weeks of starting therapy.

Improvements in Qmax were comparable to other alpha‑blockers used for BPH in head‑to‑head and pooled analyses, indicating symptomatic benefit on dynamic bladder outlet obstruction.

Patient‑reported quality of life scores improved in parallel with symptom scores in most trials, consistent with established alpha‑blocker effects on urinary bother.

Safety Observations

What safety signals should prescribers and patients watch for?

Safety data emphasised early‑treatment hypotensive events such as dizziness and, less commonly, syncope, particularly in patients already taking antihypertensives or with orthostatic susceptibility.

Comparative analyses reported lower rates of ejaculatory dysfunction with alfuzosin than with some alpha‑1A selective agents in several studies, although patient experience varies.

Trials and pooled data flagged drug–drug interaction risk via CYP3A4 inhibitors and a signal for intraoperative floppy iris syndrome recorded in ophthalmic registries.

Real‑world prescribing trends in UK and EU practice showed stable use of Xatral and generics for men intolerant of or contraindicated for tamsulosin, with many clinicians recommending once‑daily dosing after a meal to reduce hypotension.

Evidence gaps noted by investigators included limited long‑term cardiovascular outcome data and a shortage of robust UK‑based head‑to‑head trials versus silodosin.

Clinical Mechanism Of Action

Layman’s Explanation

How does the tablet make peeing easier without shrinking the prostate?

Alfuzosin relaxes the smooth muscle in the prostate and bladder neck so urine can pass more freely, but it does not reduce the size of the prostate gland.

The drug typically brings symptom relief relatively quickly and is taken once daily with food to make effects predictable and to lower the chance of sudden drops in blood pressure.

Scientific Breakdown

What is the pharmacology behind that relaxed feeling?

Alfuzosin is an alpha‑1 adrenoceptor antagonist (ATC G04CA01) that reduces smooth‑muscle tone in the lower urinary tract, diminishing dynamic obstruction at the bladder neck and prostate urethra.

Because it is not a 5‑alpha‑reductase inhibitor, it has no effect on prostate volume and will not reverse structural enlargement.

Receptor Selectivity

Which alpha subtypes does alfuzosin target?

Alfuzosin is relatively non‑subtype selective compared with alpha‑1A preferring agents such as tamsulosin and silodosin, which explains its strong clinical effect on dynamic obstruction but also the potential for blood pressure effects in some patients.

Pharmacokinetics & Food Effect

How should the tablet be taken to be safe and consistent?

Extended‑release and prolonged‑release formulations are designed for once‑daily dosing and are best absorbed when taken after the same meal every day to reduce peak plasma levels and the risk of hypotension.

Alfuzosin is largely metabolised in the liver via CYP3A4 pathways, which is important for potential drug interactions with azoles, protease inhibitors and other CYP3A4 inhibitors.

Scope Of Approved & Off‑Label Use

United Kingdom Approvals

Who can be prescribed alfuzosin in the UK and for what?

Alfuzosin, marketed as Xatral and as generics, is MHRA‑authorised and prescription‑only in the United Kingdom for the symptomatic treatment of benign prostatic hyperplasia in adult men.

The standard regimen is a 10 mg extended‑release tablet once daily after the same meal each day, and the product is not approved for children or women.

Notable Off‑Label Trends

When do clinicians sometimes use it beyond the strict licence?

In practice, UK clinicians may prescribe alfuzosin off‑label for LUTS/BPH when patients are intolerant of other alpha‑blockers or as part of combination therapy with 5‑alpha‑reductase inhibitors such as finasteride or dutasteride in men with larger prostates.

Alfuzosin is also chosen for some men where avoidance of ejaculatory disturbance is a priority, and any off‑label prescribing should be recorded with informed consent and follow local governance.

Dosage Strategy

General Dosing

What dose should a typical adult take?

The standard and recommended dose is 10 mg extended/prolonged‑release tablet taken once daily after the same meal to standardise absorption and reduce the risk of hypotension.

Lower strengths (5 mg) exist for some generic products and 2.5 mg formulations are rare; these lower doses are less commonly used in routine UK practice.

Condition‑Specific Dosing

How do dose adjustments work for special populations?

For uncomplicated BPH, use 10 mg ER daily in adults unless contraindicated.

Elderly patients usually do not require routine dose reduction, but increased sensitivity to orthostatic hypotension and falls should be considered when starting therapy.

Renal impairment typically does not require initial dose adjustment in mild to moderate dysfunction, but alfuzosin should be avoided or used only with specialist advice in severe renal insufficiency.

Hepatic impairment is an important limitation: alfuzosin is contraindicated in moderate to severe hepatic insufficiency and should be used cautiously or avoided in mild impairment as per product labelling.

If a dose is missed, the patient should take it when remembered unless it is almost time for the next dose, and they must not double up doses.

Safety Protocols

Contraindications

Who must not take alfuzosin?

Absolute contraindications include moderate or severe hepatic insufficiency and known hypersensitivity to alfuzosin or any excipients in the formulation.

Strong CYP3A4 inhibitors such as ketoconazole are contraindicated because they markedly increase alfuzosin exposure.

Adverse Effects

What side‑effects are common and which need urgent attention?

Common mild adverse effects include dizziness, headache, tiredness, upper respiratory tract symptoms and gastrointestinal upset such as nausea.

More serious events that require urgent medical review include syncope, severe hypotension, chest pain or arrhythmia and hypersensitivity reactions.

Ophthalmic surgeons should be informed of alfuzosin use prior to cataract surgery because of the risk of intraoperative floppy iris syndrome (IFIS).

Patients should be counselled to rise slowly from sitting or lying positions and have their blood pressure reviewed when starting therapy, particularly if they are taking other antihypertensive medicines.

Interaction Mapping

Food Interactions

Does food matter when taking the tablet?

Yes — absorption and peak plasma concentrations are affected by food, and the product information instructs taking alfuzosin 10 mg after the same meal each day to optimise exposure and reduce the risk of hypotension.

Drug Combinations To Avoid

Which drugs increase risk when given together with alfuzosin?

Potent CYP3A4 inhibitors such as ketoconazole and ritonavir significantly increase alfuzosin exposure and are contraindicated with standard dosing.

Combining alfuzosin with other antihypertensives, nitrates or phosphodiesterase‑5 inhibitors may produce additive hypotensive effects, so close blood pressure monitoring is required.

Concomitant use of other alpha‑blockers generally increases the risk of orthostatic hypotension and is rarely indicated.

Pharmacovigilance checks should include antifungals, macrolide antibiotics and antiretroviral agents when prescribing in UK practice because of CYP3A4 interaction potential.

Patient Experience Analysis

Survey Data

Do patients actually notice improvements and what stops them from continuing?

Practice audits and patient‑reported outcome studies indicate many men experience rapid symptomatic relief on alfuzosin, often reporting improved flow and reduced nocturia within weeks.

Common reasons for stopping treatment are dizziness and fatigue, particularly in older patients where falls risk is a concern.

Adherence tends to be higher when the regimen is once daily and taken after a consistent meal, while morning hypotension and worries about interactions are common adherence barriers.

Forum Trends

What do men say online and how should pharmacists respond?

Forum and patient‑support discussion themes include questions about switching between brands and generics, concerns about sexual side‑effects, and whether to stop antihypertensives when starting alfuzosin.

Patients also frequently ask about cataract surgery warnings and brand differences such as Xatral versus generics.

Pharmacists and prescribers should proactively address these concerns and provide written counselling to support adherence and safety.

Distribution & Pricing Landscape

Manufacturers & Market Share

Who supplies Xatral and the common generics in the UK?

Sanofi is the originator for Xatral, and major generic suppliers active across UK and EU markets include Teva, Sandoz, Mylan, Krka, Actavis and Torrent.

NHS and local formularies often favour cost‑effective generic formulations where bioequivalence is demonstrated.

UK Pricing & Prescribing

How cheap is alfuzosin and how is it prescribed in the NHS?

Generic availability has substantially reduced cost per item compared with originator brands, and local commissioning and prescribing guidance determine preferred brands and switches for cost‑saving.

Blister pack sizes of 30 or 60 affect dispensing quantities and stock management, and pharmacists must counsel patients about meal timing whenever switching brands to maintain consistent absorption.

For private prescriptions the brand chosen can affect price; NHS prescriptions follow local commissioning decisions and may favour a particular generic supplier.

In our online pharmacy, xatral is available without a prescription, with discreet delivery to United Kingdom in 5‑14 days.

Alternative Options

Comparison Table (Text)

Which drugs are typically compared when treating BPH?

Alfuzosin is generally compared with tamsulosin and silodosin (alpha‑1A preferring agents) and older non‑selective agents such as terazosin and doxazosin.

5‑alpha‑reductase inhibitors (finasteride and dutasteride) are mechanistically different and are used to reduce prostate volume over months rather than provide rapid symptom relief.

Pros And Cons

How should a choice be made for an individual man?

Alfuzosin pros: rapid symptom relief, once‑daily extended‑release formulation and reported lower ejaculatory disturbance than some alpha‑1A selective agents in certain analyses.

Alfuzosin cons: contraindicated in moderate–severe hepatic impairment, carries a hypotension risk and has important interactions via CYP3A4.

Tamsulosin/silodosin pros: greater uroselectivity and potentially less effect on blood pressure.

Tamsulosin/silodosin cons: silodosin has a higher rate of ejaculatory dysfunction in many clinical reports.

Terazosin/doxazosin pros: useful if treating concurrent hypertension as they lower blood pressure.

Terazosin/doxazosin cons: higher risk of orthostatic hypotension compared with modern ER alpha‑blockers.

5ARI pros: reduce prostate size and risk of progression over months to years.

5ARI cons: slow onset of benefit and potential sexual side‑effects; best used in men with demonstrably enlarged prostates where long‑term reduction in progression is desired.

Choice depends on comorbidities, prostate size, patient priorities and tolerability.

Regulatory Status

International Approvals

Where is alfuzosin authorised beyond the UK?

Alfuzosin (INN: alfuzosin) is FDA‑approved in the USA as Uroxatral, authorised across EU markets as Xatral and authorised by national agencies such as ANMDMR in Romania.

It is MHRA‑authorised in the United Kingdom, TGA‑listed in Australia and authorised by Health Canada, and remains a prescription‑only medicine internationally.

Pharmacovigilance & Prescribing UK

How should adverse reactions be reported and what should prescribers check?

Suspected adverse drug reactions should be reported via the MHRA Yellow Card scheme in the UK.

Product labelling highlights contraindication in moderate to severe hepatic insufficiency and warns about strong CYP3A4 inhibitors and IFIS risk.

Local formularies and commissioning policies should be checked for preferred generics or brand recommendations before prescribing.

Consolidated FAQ

Short Q&A (Clinician + Patient)

Can women or children take alfuzosin?

No — the indication is adult men with BPH only.

When should the tablet be taken?

Take 10 mg extended‑release once daily after the same meal each day to standardise absorption and reduce hypotension risk.

What if I miss a dose?

Take it when you remember unless it is almost time for the next dose; do not double up.

Can I drive?

Exercise caution; if dizziness occurs do not drive until you are confident it has settled.

Is it safe with antihypertensives?

Use with care because of additive hypotensive effects; review the patient’s blood pressure and medicines and monitor after initiating alfuzosin.

What about cataract surgery?

Inform the ophthalmic surgeon because of the risk of intraoperative floppy iris syndrome (IFIS).

How should the medicine be stored?

Store at room temperature (20–25°C), protect from moisture and heat and keep in the original packaging.

Visual Guide

Recommended Infographic Elements

What should a one‑page clinician or patient infographic include?

Mechanism diagram showing prostate and bladder neck relaxation with the caption: “Alfuzosin relaxes smooth muscle; does not shrink prostate.”

Dosing timeline image showing “10 mg once daily after same meal.”

Quick safety icons for hypotension, IFIS and hepatic contraindication.

Interaction map highlighting CYP3A4 inhibitors and antihypertensives.

Packaging images of Xatral and common generics in blister packs.

Action checklist for surgery and medication review to cue prescribers and pharmacists.

Suggested Captions & Alt Text

Suggested alt‑text for the infographic: “Infographic: alfuzosin (Xatral) dosing, contraindications and interactions for UK prescribers.”

Use accessible colours and NHS‑style iconography for clarity in primary care materials.

Storage & Transport

Pharmacy & Patient Guidance

How should pharmacies and patients handle Xatral and generics?

Store at room temperature (20–25°C) and protect from moisture and heat, retaining the medicine in original packaging as per product information.

Dispense in sealed blister packs when available to maintain formulation stability, and advise patients to remove tablets from blister only at time of use and to avoid storage in bathrooms.

Logistics For Prescribers

What should prescribers know about supply?

Manufacturers supply via standard non‑cold‑chain routes but products should remain within the labelled temperature range during storage and shipment.

For repeat prescriptions, try to maintain the same brand where possible to reduce patient concern about perceived differences between generics and originator brands.

Guidelines For Proper Use

Prescribing Checklist (UK)

What checks should be completed before initiating alfuzosin?

Confirm BPH diagnosis and record baseline IPSS where possible.

Check hepatic function — alfuzosin is contraindicated in moderate to severe hepatic impairment.

Review the full medication list for CYP3A4 inhibitors and antihypertensives and assess fall and orthostatic‑hypotension risk.

Document any planned cataract surgery and inform ophthalmology teams.

Counselling Points For Patients

What should pharmacists tell people starting treatment?

Take the 10 mg extended‑release tablet after the same meal each day, and do not crush or chew the tablet unless the product information allows it.

Warn about dizziness and advise rising slowly from sitting or lying positions.

Advise patients not to stop antihypertensives or other medicines without speaking to the prescriber, and to report syncope, chest pain or severe hypotension immediately.

Arrange a review within 4–12 weeks after initiation and schedule annual reviews thereafter if treatment continues.

Documentation Template

A brief documentation template to use in records: indication; baseline IPSS score; medication list checked (recorded); hepatic and renal status noted; counselling on meal timing, IFIS and hypotension provided; review date scheduled.

Delivery Across United Kingdom

Frequently Asked Clinical Points

Is Alfuzosin Suitable For Men On Multiple Medicines?

Always review the full medication list for CYP3A4 inhibitors and drugs that lower blood pressure before prescribing alfuzosin.

When interactions are possible, consider alternative treatments or adjust monitoring frequency rather than assuming safety.

When Should A Patient Be Referred Back To Secondary Care?

Refer if severe hypotension, recurrent syncope, chest pain, new arrhythmia, severe allergic reaction or significant deterioration in urinary symptoms occurs despite therapy.

Also refer patients with rapidly progressive renal impairment or complex polypharmacy requiring specialist medication reconciliation.

What Monitoring Is Needed?

Check blood pressure at baseline and after starting therapy, especially in patients on antihypertensives.

Reassess symptoms and tolerance within 4–12 weeks and document benefits versus adverse effects to inform ongoing prescribing.

Closing Practical Advice

Offer clear written instructions to patients: record the time of day and the meal used when taking the tablet to keep dosing consistent.

Remind men to tell all healthcare providers, including ophthalmic teams, that they use alfuzosin before any eye surgery.

Encourage reporting of suspected adverse reactions to the MHRA Yellow Card scheme and document all counselling in the medical record.

Delivery Across United Kingdom